Market Overview

Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort in Metastatic Castration-Resistant Prostate Cancer

Exelixis (NASDAQ: EXEL) today announced interim data from 51
patients with metastatic castration-resistant prostate cancer (CRPC) and
bone metastases receiving a 40 mg daily dose of cabozantinib in an
ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized
discontinuation trial. The data suggest that the 40 mg daily dose has
similar clinical activity to the 100 mg daily dose previously reported
from this trial for key parameters, including reduction of metastatic
bone and soft tissue disease, and reduction of bone-related pain and
narcotic use, with apparent improvement in adverse event rates and
tolerability. Johann de Bono, M.D., Ph.D., leader of the prostate cancer
targeted therapy team at The Institute of Cancer Research, London, and
honorary consultant at The

See full press release

Posted-In: News Guidance

 

Related Articles (EXEL)

Around the Web, We're Loving...

Get Benzinga's Newsletters